Erythromycin
Benzamycin, E.e.s, Ery-tab, Eryc, Erygel, Eryped, Erythrerm, Erythrocin, Erythromycin, Eryzole, Ilosone, Ilotycin, Pediazole (erythromycin) is a small molecule pharmaceutical. Erythromycin was first approved as Ilotycin on 1982-01-01. It is used to treat acne vulgaris, bacterial eye infections, bacterial infections, campylobacter infections, and chancroid amongst others in the USA. It is known to target motilin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Trade Name
FDA
EMA
E.e.s, Eryc, Erygel, Eryped, Erythrocin (generic drugs available since 1982-01-01, discontinued: A/t/s, Akne-mycin, Bristamycin, C-solve, E-base, E-glades, E-mycin, E-solve, E.e.s., Emgel, Eryc sprinkles, Erycette, Eryderm, Erymax, Erypar, Erythro-statin, Ethril, Ilosone, Ilotycin, Pce, Pediamycin, Pfizer, R-p mycin, Robimycin, Sansac, Staticin, T-stat, Wyamycin)
CombinationsBenzamycin (generic drugs available since 1982-01-01, discontinued: Aktipak, Eryzole, Ilosone sulfa, Pediazole)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Benzoyl peroxide
+
Erythromycin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| BENZAMYCIN | Bausch Health Companies | N-050557 RX | 1984-10-26 | 1 products, RLD, RS |
Show 1 discontinued
Erythromycin
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ERYC | Mayne Group | N-050536 RX | 1982-01-01 | 1 products, RLD, RS |
| ERYGEL | Mylan | N-050617 RX | 1987-10-21 | 1 products, RLD, RS |
Show 8 discontinued
Erythromycin estolate
Erythromycin estolate
+
Sulfisoxazole acetyl
Erythromycin ethylsuccinate
Erythromycin ethylsuccinate
+
Sulfisoxazole acetyl
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| PEDIAZOLE | Ross Laboratories | N-050529 DISCN | 1982-01-01 | 1 products |
Hide discontinued
Erythromycin gluceptate
Tradename | Company | Number | Date | Products |
|---|---|---|---|---|
| ILOTYCIN GLUCEPTATE | Dista Products | N-050370 DISCN | 1982-01-01 | 3 products |
Hide discontinued
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| benzamycin | New Drug Application | 2020-11-30 |
| e.e.s | New Drug Application | 2011-04-18 |
| e.e.s e.e.s | ANDA, New Drug Application | 2023-12-16 |
| ery | ANDA | 2022-04-22 |
| ery-ped | New Drug Application | 2023-12-16 |
| ery-tab | ANDA | 2023-09-26 |
| erygel | New Drug Application | 2018-06-21 |
| erythrocin lactobionate | New Drug Application | 2023-09-26 |
| erythrocin stearate | ANDA | 2023-09-22 |
| erythromycin | ANDA | 2024-01-16 |
Show 7 more
Indications
FDA
EMA
Show 7 more
Agency Specific
FDA
EMA
Expiration | Code | ||
|---|---|---|---|
ERYTHROMYCIN, ERYTHROMYCIN, TORRENT | |||
| 2022-04-02 | CGT | ||
Patent Expiration
No data
ATC Codes
D: Dermatologicals
— D10: Anti-acne preparations
— D10A: Anti-acne preparations for topical use
— D10AF: Antiinfectives for treatment of acne
— D10AF02: Erythromycin
— D10AF52: Erythromycin, combinations
J: Antiinfectives for systemic use
— J01: Antibacterials for systemic use
— J01F: Macrolides, lincosamides and streptogramins
— J01FA: Macrolides
— J01FA01: Erythromycin
S: Sensory organ drugs
— S01: Ophthalmologicals
— S01A: Antiinfective ophthalmologics
— S01AA: Antibiotics, ophthalmologic
— S01AA17: Erythromycin
HCPCS
Code | Description |
|---|---|
| J1364 | Injection, erythromycin lactobionate, per 500 mg |
Clinical
Clinical Trials
2151 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Depression | D003863 | — | F33.9 | 1 | — | 1 | 2 | 57 | 61 |
| Neuroblastoma | D009447 | EFO_0000621 | — | 15 | 26 | 12 | 1 | 4 | 55 |
| Healthy volunteers/patients | — | — | — | 37 | 4 | 1 | 5 | 5 | 49 |
| Obesity | D009765 | EFO_0001073 | E66.9 | 2 | 2 | 2 | 2 | 37 | 44 |
| Acne vulgaris | D000152 | EFO_0003894 | L70 | 6 | 3 | 3 | 10 | 15 | 36 |
| Covid-19 | D000086382 | — | U07.1 | 9 | 11 | 4 | 1 | 14 | 34 |
| Type 2 diabetes mellitus | D003924 | EFO_0001360 | E11 | 3 | 1 | 1 | 2 | 17 | 23 |
| Hypertension | D006973 | EFO_0000537 | I10 | — | — | — | 1 | 18 | 19 |
| Infections | D007239 | EFO_0000544 | — | 1 | 2 | — | 3 | 12 | 17 |
| Multiple myeloma | D009101 | — | C90.0 | 11 | 6 | 1 | 1 | 1 | 16 |
Show 80 more
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Neoplasms | D009369 | — | C80 | 26 | 7 | 2 | — | 20 | 50 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | 8 | 11 | 8 | — | 24 | 49 |
| Prostatic neoplasms | D011471 | — | C61 | 6 | 8 | 12 | — | 5 | 30 |
| Smoking cessation | D016540 | EFO_0004319 | — | 1 | 1 | 2 | — | 21 | 25 |
| Hiv infections | D015658 | EFO_0000764 | B20 | 7 | 5 | 7 | — | 5 | 22 |
| Cardiovascular diseases | D002318 | HP_0001626 | — | 1 | — | 1 | — | 17 | 19 |
| Leukemia | D007938 | — | C95 | 10 | 6 | 3 | — | 3 | 18 |
| Colorectal neoplasms | D015179 | — | — | 5 | 2 | 1 | — | 12 | 18 |
| Non-small-cell lung carcinoma | D002289 | — | — | 5 | 6 | 3 | — | 4 | 17 |
| Lymphoma | D008223 | — | C85.9 | 11 | 6 | 1 | — | 2 | 17 |
Show 91 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Stroke | D020521 | EFO_0000712 | I63.9 | 1 | 2 | — | — | 13 | 16 |
| Non-hodgkin lymphoma | D008228 | — | C85.9 | 10 | 5 | — | — | — | 13 |
| Melanoma | D008545 | — | — | 6 | 3 | — | — | 5 | 13 |
| Myeloid leukemia acute | D015470 | — | C92.0 | 7 | 5 | — | — | — | 10 |
| Uterine cervical neoplasms | D002583 | HP_0030159 | — | 3 | 4 | — | — | 2 | 9 |
| Hodgkin disease | D006689 | — | C81 | 7 | 2 | — | — | — | 8 |
| Chronic renal insufficiency | D051436 | — | N18 | 1 | 1 | — | — | 6 | 8 |
| Type 1 diabetes mellitus | D003922 | EFO_0001359 | E10 | 1 | 3 | — | — | 4 | 8 |
| Glioblastoma | D005909 | EFO_0000515 | — | 5 | 4 | — | — | 1 | 8 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | — | 1 | — | — | 7 | 8 |
Show 132 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Heart failure | D006333 | HP_0001635 | I50 | 1 | — | — | — | 17 | 18 |
| Overweight | D050177 | — | E66.3 | 1 | — | — | — | 13 | 14 |
| Post-traumatic stress disorders | D013313 | EFO_0001358 | F43.1 | 1 | — | — | — | 9 | 10 |
| Diabetes mellitus | D003920 | HP_0000819 | E08-E13 | 1 | — | — | — | 8 | 9 |
| Sarcoma | D012509 | — | — | 4 | — | — | — | 3 | 7 |
| Aging | D000375 | GO_0007568 | R41.81 | 1 | — | — | — | 6 | 7 |
| Diet therapy | D004035 | — | — | 1 | — | — | — | 5 | 6 |
| Shoulder pain | D020069 | HP_0030834 | M25.51 | 1 | — | — | — | 4 | 5 |
| Mindfulness | D064866 | — | — | 1 | — | — | — | 3 | 4 |
| Recurrence | D012008 | — | — | 1 | — | — | — | 3 | 4 |
Show 89 more
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Anxiety | D001007 | EFO_0005230 | F41.1 | — | — | — | — | 25 | 25 |
| Smoking | D012907 | EFO_0004318 | — | — | — | — | — | 17 | 17 |
| Low back pain | D017116 | HP_0003419 | M54.5 | — | — | — | — | 12 | 12 |
| Tobacco use | D064424 | — | Z72.0 | — | — | — | — | 12 | 12 |
| Psychotic disorders | D011618 | — | F20.81 | — | — | — | — | 11 | 11 |
| Anxiety disorders | D001008 | EFO_0006788 | F41.1 | — | — | — | — | 11 | 11 |
| Obstructive sleep apnea | D020181 | EFO_0003918 | G47.33 | — | — | — | — | 11 | 11 |
| Chronic pain | D059350 | HP_0012532 | — | — | — | — | — | 10 | 10 |
| Coronary artery disease | D003324 | — | I25.1 | — | — | — | — | 9 | 9 |
| Health behavior | D015438 | — | — | — | — | — | — | 8 | 8 |
Show 428 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Erythromycin |
| INN | erythromycin |
| Description | Erythromycin A is an erythromycin that consists of erythronolide A having 2,6-dideoxy-3-C-methyl-3-O-methyl-alpha-L-ribo-hexopyranosyl and 3,4,6-trideoxy-3-(dimethylamino)-beta-D-xylo-hexopyranosyl residues attahced at positions 4 and 6 respectively. It is an erythromycin and a cyclic ketone. It is functionally related to an erythronolide A. It is a conjugate base of an erythromycin A(1+). |
| Classification | Small molecule |
| Drug class | antibiotics (Streptomyces strains) |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(O)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O |
Identifiers
| PDB | — |
| CAS-ID | 114-07-8 |
| RxCUI | — |
| ChEMBL ID | CHEMBL532 |
| ChEBI ID | 42355 |
| PubChem CID | 12560 |
| DrugBank | DB00199 |
| UNII ID | 63937KV33D (ChemIDplus, GSRS) |
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Erythromycin
+
Benzoyl peroxide
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Erythromycin
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Erythromycin
+
Sulfisoxazole
Total medical expenditures per year (USD, in millions)
Mock data
Subscribe for the real data
Subscribe for the real data
Number of persons purchased
Mock data
Subscribe for the real data
Subscribe for the real data
Number of purchases
Mock data
Subscribe for the real data
Subscribe for the real data
Refill frequency
Mock data
Subscribe for the real data
Subscribe for the real data
Price per prescription (USD)
Mock data
Subscribe for the real data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 81,537 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
9,118 adverse events reported
View more details
© 2020-2024 Collaborative Drug Discovery Inc. (CDD) | Terms of Use